Clinical Trial Update: SIMPADICO - Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes [Phase 3]

View source ↗

Summary

Phase 3 trial SIMPADICO investigating immune modulation therapy in peripheral arterial disease and intermittent claudication was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arterial Occlusive Disease
• Intermittent Claudication
• Peripheral Arterial Disease

Drugs mentioned

• SIMPADICO

Snippet

Sponsor: Vasogen | Conditions: Peripheral Arterial Disease, Arterial Occlusive Diseases | Phase 3 | Status: TERMINATED